

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

A021502 STUDY DOCUMENTS

**RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB
AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA
MISMATCH REPAIR (ATOMIC)**

ClinicalTrials.gov Identifier: NCT02912559

Study Activation Date: 09/12/2017

Study Closure Date: N/A

Patient Follow-up Termination Date: N/A

| DOCUMENT NAME | EFFECTIVE DATE | ALLIANCE POSTING DATE |
|--|-----------------------|------------------------------|
| Activation (NCI Version 07/13/2017) Memorandum Re: Requirements for NDA/Registration Trial | 09/12/2017 | 09/12/2017 |
| Update #01 (NCI Version 11/02/2017) Memorandum Re: Delegation of Task Log Activation | | 12/15/2017 |
| Update #02 (NCI Version 05/08/2018) Correlative Science Manual | | 07/15/2018 |
| Update #03 (NCI Version 07/09/2018) Memorandum Re: Delegation of Task Log Revision | | 08/01/2018 |
| Update #04 (NCI Version 09/21/2018) Atezolizumab Action Letter Broadcast Re: Action Letter: Immediate Action Required | | 10/05/2018 |
| Update #05 (NCI Version 02/05/2019) | | 03/01/2019 |
| Update #06 (NCI Version 06/30/2020) | | 08/01/2020 |
| Update #07 (NCI Version 10/29/2020) | | 12/15/2020 |
| Update #08 (NCI Version 04/08/2021) | | 05/01/2021 |
| Updated #09 (NCI Version 06/07/2021) Atezolizumab Action Letter Broadcast Re: Action Letter: Immediate Action Required | | 06/23/2021 |
| Action Required 06/23/2021 Update #10 (NCI Version 10/15/2021) | | 12/15/2021 |
| Update #11 (NCI Version 08/01/2022) | | 09/01/2022 |
| Update #12 (NCI Version 08/25/2022) | | 09/30/2022 |